A 30-years review on pharmacokinetics of antibiotics: is the right time for pharmacogenetics?
A 30-years review on pharmacokinetics of antibiotics: is the right time for pharmacogenetics?
复制标题
DOI：
10.2174/1389200215666140605130935
复制
发表时间：
2014
影响因子：
2.3
通讯作者：
De Rosa FG
中科院分区：
文献类型：
--
作者：
Baietto L;Corcione S;Pacini G;Perri GD;D'Avolio A;De Rosa FG
药物的生物利用度在个体之间可能有很大差异，影响疗效和毒性：在人类中，遗传变异在这种变异中占了相当大的比例。在过去的十年中，药物遗传学在临床实践中的使用，作为一种个性化治疗的工具，在不同的临床领域显示出不同程度的普及。在传染病领域，一些研究发现宿主基因多态与抗逆转录病毒治疗反应之间存在大量关联。例如，在接受阿巴卡韦治疗的患者中，在开始治疗之前对HLA-B*5701进行筛查是所有患者的常规临床实践和护理标准；Eefavirenz的血浆水平受到单核苷酸多态(SNP)CYP2B6-516G>(Rs3745274)的影响。关于抗生素，许多研究调查了与抗生素生物利用度有关的药物转运体，特别是氟喹诺酮类、头孢菌素类和抗结核药物。到目前为止，关于新近开发的抗生素，如替吉环素、达托霉素或利奈唑胺的药物遗传学数据很少。考虑到SNPs在编码参与抗生素生物利用度的蛋白质的基因中的作用，很少有数据发表。增加抗生素药物遗传学领域的知识可能有助于解释患者之间高度的药物变异性，并使治疗个体化。在这篇文章中，我们报告了抗生素的药代动力学、药效学和药物遗传学的概述，以强调在临床实践中选择正确剂量的综合方法的重要性。
Drug bioavailability may vary greatly amongst individuals, affecting both efficacy and toxicity: in humans, genetic variations account for a relevant proportion of such variability. In the last decade the use of pharmacogenetics in clinical practice, as a tool to individualize treatment, has shown a different degree of diffusion in various clinical fields. In the field of infectious diseases, several studies identified a great number of associations between host genetic polymor-phisms and responses to antiretroviral therapy. For example, in patients treated with abacavir the screening for HLA-B*5701 before starting treatment is routine clinical practice and standard of care for all patients; efavirenz plasma levels are influenced by single nucleotide polymorphism (SNP) CYP2B6-516G> T (rs3745274). Regarding antibiotics, many studies investigated drug transporters involved in antibiotic bioavailability, especially for fluoroquinolones, cephalosporins, and antituberculars. To date, few data are available about pharmacogenetics of recently developed antibiotics such as tigecycline, daptomycin or linezolid. Considering the effect of SNPs in gene coding for proteins involved in antibiotics bioavailability, few data have been published. Increasing knowledge in the field of antibiotic pharmacogenetics could be useful to explain the high drug inter-patients variability and to individualize therapy. In this paper we reported an overview of pharmacokinetics, pharmacodynamics, and pharmacogenetics of antibiotics to underline the importance of an integrated approach in choosing the right dosage in clinical practice.
登录
查看更多内容
DOI：
10.1111/j.1476-5381.1967.tb01946.x
发表时间：
1967-01-01
期刊：
BRITISH JOURNAL OF PHARMACOLOGY AND CHEMOTHERAPY
影响因子：
--
作者：
BEVERIDGE, EG;MARTIN, AJ
通讯作者：
MARTIN, AJ
影响因子：
4.4
作者：
Ambrose, PG;Bhavnani, SM;Owens, RC
通讯作者：
Owens, RC
DOI：
10.1177/106002808802200404
发表时间：
1988-04-01
期刊：
DRUG INTELLIGENCE & CLINICAL PHARMACY
影响因子：
--
作者：
ACKERMAN, BH;TAYLOR, EH;PAPPAS, AA
通讯作者：
PAPPAS, AA
影响因子：
2.1
作者：
Arakawa, Hiroshi;Shirasaka, Yoshiyuki;Tamai, Ikumi
通讯作者：
Tamai, Ikumi
DOI：
10.1177/106002809102501101
发表时间：
1991-11-01
期刊：
DICP-THE ANNALS OF PHARMACOTHERAPY
影响因子：
--
作者：
BOSSO, JA;LIPTAK, CA;HARRISON, GM
通讯作者：
HARRISON, GM